Case number 1:23-cv-01050
Fresenius Kabi USA, LLC v. Meitheal Pharmaceuticals, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Dec 18, 2023 | 8 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,476,010 B2. (Attachments: # 1 Notice of Dismissal)(kmd) (Entered: 12/18/2023) (0) |
| Dec 15, 2023 | 7 | NOTICE of Voluntary Dismissal by Fresenius Kabi USA, LLC as to All Claims (Farnan, Brian) (Entered: 12/15/2023) (2) |
| Dec 15, 2023 | N/A | CASE CLOSED per 7 Notice of Dismissal. (kmd) (Entered: 12/18/2023) (0) |
| Sep 28, 2023 | 6 | STANDING ORDER REGARDING BRIEFING IN ALL CASES (nmf) (Entered: 09/28/2023) (2) |
| Sep 27, 2023 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 09/27/2023) (0) |
| Sep 26, 2023 | 1 | Complaint* (1) |
| Sep 26, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) (Entered: 09/26/2023) (3) |
| Sep 26, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/14/2023. Date of Expiration of Patent: 6/1/2025.Thirty Month Stay Deadline: 2/14/2026. (apk) (Entered: 09/26/2023) (2) |
| Sep 26, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,476,010 B2. (apk) (Entered: 09/26/2023) (1) |
| Sep 26, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Fresenius Kabi AG, Corporate Parent Fresenius SE & Co. KGaA, Corporate Parent Fresenius Kabi Pharmaceuticals Holding, LLC for Fresenius Kabi USA, LLC filed by Fresenius Kabi USA, LLC. (apk) (Entered: 09/26/2023) (2) |
| Sep 26, 2023 | N/A | No Summons Issued. (apk) (Entered: 09/26/2023) (0) |
